Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts. First Opinion is STAT ...

Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also ...

A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second try at approval.

The Justice Department's actions on illegal vapes pales next to the scale of the problem, anti-smoking advocates say.

The panel had become a flashpoint as RFK Jr.'s health department worked to limit the number of recommended childhood shots.

The Trump administration this week acknowledged it made a significant error in figures it used to help justify a fraud ...

In my most honest of moments, what I want from the medical community is the chance to trust it again,” a MAHA advocate writes ...

CAR-T therapy is toting up more remissions in autoimmune disease, and generating a flood of experimentation and investment.

CAR-T therapies are continuing to gain traction in autoimmune disease, with a notable new case. Also, the FDA has withdrawn ...

Zac Jiwa, a federal Medicare official, delivered a eulogy of sorts at a Thursday Medicare event highlighting the successes of ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

In December, Trump said he would summon health insurance execs to the White House. It doesn't seem a meeting ever happened.